| Autor: |
Aliberti S; IRCCS Humanitas Research Hospital, Respiratory Unit, Pieve Emanuele, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy., Chalmers JD; Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK j.chalmers@dundee.ac.uk. |
| Abstrakt: |
Competing Interests: Conflict of interest: S. Aliberti reports grants or contracts from Insmed Incorporated, Chiesi, Fisher and Paykel, and GSK, royalties or licences from McGraw Hill, consulting fees from Insmed Incorporated, Insmed Italy, Insmed Ireland Ltd, Zambon Spa, AstraZeneca UK Ltd, AstraZeneca Pharmaceutical LP, CSL Behring GmbH, Grifols, Fondazione internazionale Menarini, Moderna, Chiesi, MCD Italis SrL, Brahms, Physioassist SAS and GlaxoSmithKline Spa, payment or honoraria for lectures, presentations, manuscript writing or educational events from GlaxoSmithKline Spa, Thermofisher Scientific, Insmed Italy, Insmed Ireland, Zambon and Fondazione Internazionale Menarini, and participation on a data safety monitoring board or advisory board with Insmed Incorporated, Insmed Italy, AstraZeneca UK Ltd and MSD Italia Srl. J.D. Chalmers reports grants or contracts from AstraZeneca, Boehringer Ingelheim, Genentech, Gilead Sciences, GlaxoSmithKline, Grifols, Insmed, LifeArc and Novartis, and consulting fees from AstraZeneca, Chiesi, GlaxoSmithKline, Insmed, Grifols, Novartis, Boehringer Ingelheim, Pfizer, Janssen, Antabio and Zambon. |
